A recent study published in Blood Transfusion (2023; doi: 10.2450/BloodTransfus.492) details the successful validation of WhiteNest Pharma’s BioNest 2.0 system in a multi-component cord blood banking exercise. This international study, involving 12 public cord blood banks from Spain, Italy, Greece, the UK, and Singapore, signifies a pivotal development in the field of regenerative medicine.
The research aimed to establish a standardized process for creating cord blood platelet concentrate (CB-PC), platelet-poor plasma (CB-PPP), and leukoreduced red blood cells (CB-LR-RBC) utilizing the BioNest 2.0 system. With over 80% of umbilical cord blood units traditionally discarded due to low stem cell counts, this validation marks a critical advancement towards reducing waste and expanding the use of cord blood in clinical settings.
The study’s protocol involved a double centrifugation process to extract CB-PC, CB-PPP, and CB-RBC, with further treatments like leukoreduction and gamma irradiation. Results demonstrated a 99% compliance for volume and an 86.1% compliance for platelet count in CB-PC, among other successes, illustrating the BioNest 2.0 system’s capability to meet stringent quality standards.
The implications of this validation extend beyond cord blood banking, opening new avenues for the use of cord blood components in treatments for wound healing, corneal ulcers, and neonatal transfusions. WhiteNest Pharma is dedicated to furthering research and development in this area, enhancing the economic and clinical value of cord blood banking globally.
The BioNest 2.0 system’s validation as reported in Blood Transfusion reinforces WhiteNest Pharma’s commitment to innovation in healthcare. By improving the efficiency and application of cord blood banking, we take a significant step towards maximizing the therapeutic potential of cord blood components.